Bio-Thera Kicks Off Phase III Trial For Stelara Rival
Chinese Biosimilars Developer Begins Study For BAT2206 Ustekinumab Candidate
Bio-Thera has joined the ranks of biosimilars developers that have rivals to Stelara in Phase III trials, after kicking off a study for its BAT2206 proposed version of ustekinumab.
You may also be interested in...
Deal-happy Bio-Thera Solutions has signed another license and supply agreement, agreeing to out-license its BAT2206 biosimilar ustekinumab candidate in Russia and other CIS countries to local player Pharmapark.
Japan’s Meiji Seika Pharma and Korea’s Dong-A have struck an exclusive licensing deal with Intas for global rights to the pair’s DMB-3115 proposed ustekinumab biosimilar to Stelara.
Samsung Bioepis has become the latest firm to move an ustekinumab biosimilar into Phase III trials, with the firm’s SB17 proposed Stelara rival kicking off a study in plaque psoriasis patients.